Neoadjuvant therapy with immunoagent (nivolumab) or placebo plus chemotherapy followed by surgery and adjuvant treatment in subjects with resectable esophageal squamous cell carcinoma: study protocol of a randomized, multicenter, double blind, phase II trial (NATION-2203 trial)

BACKGROUND: Neoadjuvant chemotherapy (nCT) has been the recommended treatment for locally advanced esophageal squamous cell carcinoma (ESCC). The addition of programmed cell death protein 1 (PD-1) inhibitor to nCT may improve oncologic outcome and survival. However, high-level evidence of neoadjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Jun, Lin, Siyun, Fang, Yong, Jiao, Heng, Chen, Zongwei, Tang, Han, Gu, Jianmin, Zhang, Shaoyuan, Sun, Linyi, Li, Yin, Han, Yongtao, Chen, Qixun, Chen, Haiquan, Li, Zhigang, Tan, Lijie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992557/
https://www.ncbi.nlm.nih.gov/pubmed/36910109
http://dx.doi.org/10.21037/jtd-22-1789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992557/
https://www.ncbi.nlm.nih.gov/pubmed/36910109
http://dx.doi.org/10.21037/jtd-22-1789

Ejemplares similares